As a result Pfizer the maker of Exubera has updated labeling to include a warning with safety information about lung cancer cases found in patients who used the inhaled insulin. Exubera was approved in January of 2006 as a possible alternative for diabetics to avoid needle sticks.
The warning label stems from an ongoing review of data from the Exubera clinical trial program by the company and the FDA.
Pfizer says it will stop marketing Exubera in October.
